Literature DB >> 17564754

Aortic preadipocyte differentiation into adipocytes induced by rosiglitazone in an in vitro model.

Miguel R Reyes1, Brissia Lazalde.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a key transcription factor for adipocyte differentiation. Preadipocyte differentiation into adipocytes from precursors in blood vessels is an important issue related to atherosclerotic cardiovascular disease; however, it has been poorly studied because of lack of experimental models. Our aim was to evaluate the potential of primary outgrowths derived from rat aortic rings as a model for studying the preadipocyte differentiation from aortic precursors induced by thiazolidinediones, which are exogenous ligands for PPARgamma. Cell outgrowths derived from rat aortic rings were cultured and incubated with rosiglitazone at 1-1,000 nM; presence of lipid droplets was evaluated by oil red O staining. Rosiglitazone at 100 nM exerted a clear adipogenic effect inferred from the cells filled with fine and medium size lipidic droplets; this effect was extreme at 1,000 nM with cells showing lipidic macrodroplets. These results showed that cultures derived from aortic rings are a useful model for studying arterial preadipocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17564754     DOI: 10.1007/s11626-007-9036-2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  15 in total

Review 1.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

Review 2.  Adipogenesis: usefulness of in vitro and in vivo experimental models.

Authors:  J Novakofski
Journal:  J Anim Sci       Date:  2004-03       Impact factor: 3.159

3.  A Nuclear Receptor Atlas: 3T3-L1 adipogenesis.

Authors:  Mingui Fu; Tingwan Sun; Angie L Bookout; Michael Downes; Ruth T Yu; Ronald M Evans; David J Mangelsdorf
Journal:  Mol Endocrinol       Date:  2005-07-28

4.  Temporal and spatial variations of lipid droplets during adipocyte division and differentiation.

Authors:  Masafumi Nagayama; Tsutomu Uchida; Kazutoshi Gohara
Journal:  J Lipid Res       Date:  2007-01       Impact factor: 5.922

Review 5.  Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.

Authors:  J-R Weng; C-Y Chen; J J Pinzone; M D Ringel; C-S Chen
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

Review 6.  PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

Authors:  T M Larsen; S Toubro; A Astrup
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

7.  Determination of rosiglitazone in coated tablets by MEKC and HPLC methods.

Authors:  Patrícia Gomes; Juliana Sippel; André Jablonski; Martin Steppe
Journal:  J Pharm Biomed Anal       Date:  2004-11-19       Impact factor: 3.935

Review 8.  Vascular effects of TZDs: new implications.

Authors:  Florian Blaschke; Robert Spanheimer; Mehmood Khan; Ronald E Law
Journal:  Vascul Pharmacol       Date:  2006-06-05       Impact factor: 5.773

9.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Authors:  Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

Review 10.  The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis.

Authors:  Subodh Verma; Paul E Szmitko
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.